within Pharmacolibrary.Drugs.ATC.V;

model V10BX03
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.8333333333333335e-06,
    adminDuration  = 600,
    adminMass      = 1295 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0008100000000000001,
    k12             = 0.475,
    k21             = 0.475
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V10BX03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Rhenium (186Re) etidronic acid is a radiopharmaceutical agent that consists of the radioactive isotope rhenium-186 complexed with etidronic acid (a bisphosphonate). It is primarily used for the palliative treatment of pain associated with bone metastases, particularly in cancer patients (e.g., prostate or breast cancer). The drug is not widely approved, but has seen investigational or limited use in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic estimates are based on published data from administration in adult cancer patients with painful bone metastases. These parameters reflect average values reported in the literature for this population.</p><h4>References</h4><ol><li><p>Kothari, K, et al., &amp; Pillai, MR (2001). 186Re-1,4,8,11-tetraaza cyclotetradecyl-1,4,8,11-tetramethylene phosphonic acid: a novel agent for possible use in metastatic bone-pain palliation. <i>Nuclear medicine and biology</i> 28(6) 709–717. DOI:<a href=\"https://doi.org/10.1016/s0969-8051(01)00224-4\">10.1016/s0969-8051(01)00224-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11518653/\">https://pubmed.ncbi.nlm.nih.gov/11518653</a></p></li><li><p>Liepe, K, et al., &amp; Franke, WG (2003). Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. <i>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</i> 44(6) 953–960. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12791825/\">https://pubmed.ncbi.nlm.nih.gov/12791825</a></p></li><li><p>Buffa, FM, et al., &amp; Dearnaley, DP (2003). A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer. <i>European journal of nuclear medicine and molecular imaging</i> 30(8) 1114–1124. DOI:<a href=\"https://doi.org/10.1007/s00259-003-1197-y\">10.1007/s00259-003-1197-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12761596/\">https://pubmed.ncbi.nlm.nih.gov/12761596</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V10BX03;
